Vitrolife: Analyst - ABG

New financial targets
Promising earnings outlook unchanged
Limited earnings revisions expected, down 2-4% on EBITDA


New strategy with focus on driving profitable growth

At a well attended CMD in Stockholm, management presented its new strategy and updated long-term financial targets, including a revised sales growth target and margin target for the coming five years. The market outlook for the reproductive health industry remains strong, offering 5-7% annual market growth driven by the high level of infertility globally. Access to care and affordability are the key headwinds for even higher growth rate. In order to overcome, or at least try to mitigate part of the negative headwinds, Vitrolife will continue to focus on delivering new innovative products that will improve the clinical outcome and improve the efficiency for the clinics.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/Vitrolife/Equity-research/2023/12/vitrolife---analyst/